Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6

Official Title

A Phase 2, Open-label, Multicentre, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy Administered Subcutaneously in Patients With Advanced Cutaneous Melanoma or Intravenously in Patients With Advanced Mucosal Melanoma Who Have Previously Received Anti-PD-[L]-1 Therapy - ARTISTRY-6


This study observes the antitumour activity, safety, tolerability, PK, and pharmacodynamics in patients with inoperable and/or metastatic melanoma following prior anti-PD-[L]-1 therapy

Trial Description

Primary Outcome:

  • Centrally-assessed overall response rate (ORR)
Secondary Outcome:
  • Centrally-assessed duration of response (DOR)
  • Centrally-assessed progression free survival (PFS)
  • Centrally-assessed disease control rate (DCR)
  • Centrally-assessed time to response (TTR)
  • Incidence of treatment-emergent adverse events
  • Investigator-assessed overall response rate (ORR)
  • Investigator-assessed duration of response (DOR)
  • Investigator-assessed progression free survival (PFS)
  • Investigator-assessed disease control rate (DCR)
  • Investigator-assessed time to response (TTR)
  • Investigator-assessed immune overall response rate (iORR)
  • Investigator-assessed immune duration of response (iDOR)
  • Investigator-assessed immune progression free survival (iPFS)
  • Investigator-assessed immune disease control rate (iDCR)
  • Investigator-assessed immune time to response (iTTR)

View this trial on

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society